Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns Hopkins

Drug Profile

Research programme: fms-like tyrosine kinase 3 inhibitors - Antisoma/Johns Hopkins

Alternative Names: DCAMs - Antisoma

Latest Information Update: 15 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Antisoma
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 20 May 2010 Antisoma is looking for a licensing partnership for the programme
  • 11 Jun 2008 Xanthus Pharmaceuticals has been acquired and merged into Antisoma
  • 16 Apr 2007 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top